大多数GLP-1受体激动剂采用皮下注射给药。口服索马鲁肽(semaglutide)目前唯一一种每日口服的GLP-1受体激动剂,获得FDA批准用于2型糖尿病的治疗(2019年),剂量高达每日14毫克。 目前正在OASIS试验中研究用于肥胖症患者和未患糖尿病个体的更高剂量的减重效果。 丹诺格肽(Danuglipron):在研中的口服小分子GLP-1受体激动...
The place of the GLP-1 agonists in the treatment paradigm for type 2 diabetes will evolve over the next decade.Therapeutic advances in endocrinology and metabolism.Baynes, Kevin C. R.
1. Login or Register with R&D Systems to submit a review 2. Fill out the product review form 3. You will be emailed your reward within 2 weeks email address/username * Enter your www.rndsystems.com username. password * Sign up for a R&D Systems account Register Terms and Conditions...
In recent years, an increased focus has been placed on incretin hormones, such as glucagon-like peptide-1 (GLP-1) for its glucose-lowering benefits. Several FDA-approved short-acting and long-acting GLP-1 receptor agonists (GLP-1 RAs) are available in the United States for the treatment ...
[6]EMA Statement on Ongoing Review of GLP-1 Receptor Agonists (EMA, 2023) [7]Chiappini, S. et al. Is there a risk for semaglutide misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) pharmacovigilance dataset. Pharmaceuticals 16, 994 (2023). ...
[2] Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy. N Engl J Med. 2010 Mar 4;362(9):774-7. doi: 10.1056/NEJMp1001578. Epub 2010 Feb 17. PMID: 20164475.
[4] Shi Q, Wang Y, Hao Q, et al. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials[J]. The Lancet, 2022, 399(10321): 259-269.[5] Astrup A, Rössner S, Van Gaal L, et al. Effects of liraglutide ...
[4] Seino, Y. et al. GIP and GLP-1, the two incretin hormones: Similarities and differences. Journal of Diabetes Investigation. 2010, 1, 8–23. [5] Tilinca, M. et al. A 2021 update on the use of liraglutide in the modern treatment of ‘Diabesity’: A narrative review. Medicina ...
相关研究成果以“Comparative effectiveness of GLP-1 receptor agonists on glycemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis”为题发表于顶级医学期刊英国医学杂志(BMJ-B...
6.Hosie, R. Top gastroenterologists gave a glowing review of new weight loss drugs, and ranked them in order of effectiveness. 20. 10. 2022.7.Rahhal, N. 'Everybody is on it': A 'game-changing' weight-loss drug is NYC's hottest new trend. Business Insider. 11. 04. 2023.8.Terhune...